Evotec AG announced today that its strategic alliance with Celgene has reached a first milestone triggering revenues of $ 5.0 m to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-first-milestone-in-neurodegeneration-alliance-with-celgene-4
Evotec invests in Exscientia to advance AI-driven drug discovery
Evotec AG and Exscientia Ltd („Exscientia“) today announced that Evotec has made a EUR 15 m investment to take a minority stake in Exscientia. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-invests-in-exscientia-to-advance-ai-driven-drug-discovery-5502
Evotec and MaRS Innovation establish Academic Bridge "LAB150" in Toronto
Evotec AG and MaRS Innovation („MI“) today announced the launch of „LAB150“. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-mars-innovation-establish-academic-bridge-lab150-in-toronto-5500
European Investment Bank supports Evotec´s Innovate strategy with € 75 m loan
Evotec AG and the European Investment Bank („EIB“) announced today that the EIB has granted Evotec an unsecured loan facility of up to EUR 75 m to support Evotec’s Innovate strategy. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/european-investment-bank-supports-evotecs-innovate-strategy-with-eur-75-m-loan-5498
Evotec and ABIVAX enter into strategic collaboration to develop novel antiviral agents
Evotec AG and ABIVAX today announced a strategic collaboration to discover and develop novel treatments for multiple serious viral infectious diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-abivax-enter-into-strategic-collaboration-to-develop-novel-antiviral-agents-5496
Evotec completes acquisition of Aptuit
Evotec AG today announced that, effective mid-August 2017, it has successfully completed the acquisition of Aptuit as announced in detail on 30 July 2017. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-completes-acquisition-of-aptuit-5492
Evotec announces first half year 2017 results and corporate update
Evotec AG today reported financial results and corporate updates for the first half of 2017. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-announces-first-half-year-2017-results-and-corporate-update-5490
Evotec AG to report first half-year 2017 results on 10 August 2017
Evotec AG will report its financial results for the first half of 2017 on Thursday, 10 August 2017. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-to-report-first-half-year-2017-results-on-10-august-2017-5488
Evotec and Fraunhofer IME-SP sign strategic collaboration on iPSC technology
Evotec AG today announced a strategic collaboration on induced pluripotent stem cell („iPSC“) technology with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME, ScreeningPort. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-fraunhofer-ime-sp-sign-strategic-collaboration-on-ipsc-technology-5486
Evotec to acquire Aptuit, expanding leadership in external innovation
Evotec AG and Aptuit announced today that they have entered into a definitive agreement under which Evotec will acquire Aptuit for $ 300 m. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-to-acquire-aptuit-expanding-leadership-in-external-innovation-5482